Whilst it may not be a huge deal, we thought it was good to see that the Singular Genomics Systems, Inc. (NASDAQ:OMIC) Founder, Eli Glezer, recently bought US$86k worth of stock, for US$0.43 per share. Although the purchase is not a big one, increasing their shareholding by only 4.6%, it can be interpreted as a good sign.
Check out our latest analysis for Singular Genomics Systems
The Last 12 Months Of Insider Transactions At Singular Genomics Systems
In fact, the recent purchase by Founder Eli Glezer was not their only acquisition of Singular Genomics Systems shares this year. Earlier in the year, they paid US$0.82 per share in a US$139k purchase. That means that even when the share price was higher than US$0.41 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Eli Glezer.
Eli Glezer purchased 420.00k shares over the year. The average price per share was US$0.77. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Singular Genomics Systems is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Singular Genomics Systems
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Singular Genomics Systems insiders own 15% of the company, worth about US$4.7m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
So What Does This Data Suggest About Singular Genomics Systems Insiders?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Singular Genomics Systems insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Singular Genomics Systems. Our analysis shows 5 warning signs for Singular Genomics Systems (1 makes us a bit uncomfortable!) and we strongly recommend you look at these before investing.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.